
Clinical trials
Cancer
KEYNOTE 676
Bladder cancer
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus CalmetteGuerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676).
Cancer
ANZadapt
Prostate cancer
Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer.
Cancer
C3651003
Lung cancer, pancreatic cancer, colorectal cancer
A phase 2, randomised, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of ponsegromab in patients with cancer, cachexia, and elevated concentrations of GDF-15, followed by an optional open-label treatment period.
Cancer
RC48-G001
Urothelial cancer
A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
Cancer
CA116-001
Ovarian cancer
A phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, vs. Investigator's Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Cancer
BX43361
Solid tumors
Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors
Cancer
AK105-304
Metastatic Nasopharyngeal Carcinoma
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Cancer
PETRANHA
Prostate cancer
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA)
Cancer
BO42777
Lung cancer
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
Cancer
MiniRaP-00
Prostate cancer
A feasibility study of the repurposing of prazosin to improve treatment outcomes in men receiving radiotherapy for prostate cancer (MiniRaP-00).
Cancer
Fortitude 102
Gastric cancer
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
Cancer
BREAKWATER C4221015
Metastatic colorectal cancer
A Study of Encorafenib Plus Cetuximab with or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Cancer
Ascent 03 GS-US-592-6238
Breast cancer
A randomized, open-label, phase 3 study of sacituzumab govitecan versus treatment of physician's choice in patients with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express PD-L1 or in patients previously treated with anti-PD-(L)1 agents in the early setting whose tumors do express PD-L1
Cancer
ASCENT 04 - GS-US-592-6173
Breast cancer
Study of sacituzumab govitecan-hziy and pembrolizumab versus treatment of physician's choice and pembrolizumab in patients with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer.
Cancer
SHERLOCK Protocol number: CTC 0377 / TOGA 21/011
Lung cancer
Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation.
Cancer
PACIFIC-9: D9078C00001
Lung cancer
This is a multicentre, open label, two-part study to determine whether the focal adhesion kinase (FAK) inhibitor AMP945, when given prior to dosing with gemcitabine and nab-paclitaxel, improves response to therapy in first-line patients with unresectable or metastatic pancreatic cancer.
Cancer
Amplia AMP945-PC-201
Pancreatic cancer
A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients (AMP945-PC-201)
Cancer
DESTINY-Breast06
Breast cancer
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
Cancer
FUSION FPI-1966-101
Cancer
This is a first-in-human, Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, dosimetry, biodistribution, and PK of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab and the preliminary anti-tumour activity of [225Ac]-FPI-1966 in participants with FGFR3-expressing advanced, inoperable, metastatic, and/or recurrent solid tumours. Phase 1 consists of five multiple dose escalation cohorts. Phase 2 consists of two tumour-specific cohorts and one basket cohort.
Cancer
Protocol : GS-US-587-6156
Colorectal cancer
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Cancer
ProstACT-TARGET
Prostate cancer
A Single Arm Trial of External Beam Radiation Therapy (EBRT) in Combination with 177Lu-DOTA-TLX591 Theranostic in Patients with Biochemically Recurrent, Oligometastatic, Prostate Specific Membrane Antigen- Expressing Prostate Cancer
Cancer
KEYNOTE-C93
Cancer
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
Cancer
KEYNOTE-867
Cancer
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Breast Cancer
TABITHA
Breast cancer
A study to develop a prospective multi-site registry to evaluate clinical features, types of treatment, outcomes and survival in participants with HER2 positive metastatic breast cancer managed in routine practice in Australia.
Genitourinary Cancer
SAMETA (D5086C00001)
Genitourinary cancer
A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma)
Cancer
ICP-CL-003030
Cancer
A multi-center open-label, phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-192 in patients with advanced solid tumours and FGFR gene alterations
Prostate Cancer
DECREASE
Prostate cancer
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA.
Cancer
AMGEN 20190135
Basket – Solid Tumours
A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumours With KRAS p.G12C Mutation
Prostate Cancer
CONTACT-02
Prostate cancer
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Pro
Breast Cancer
DESTINY-12
Breast cancer
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
Lung Cancer
KRYSTAL-12
Lung cancer
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation.
Prostate Cancer
RADIANT
Prostate cancer
A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.
Liver Cancer
SYS-CAPLIOX (AV-LIVPIBII-01)
Liver cancer
The aim of this study is to assess the efficacy of delivering chemotherapy treatment through the arteries directly to the liver, bypassing the main blood supply throughout the body.
Breast Cancer
HER2 REAL (D9673R00005)
Breast cancer
A Multicountry, Multicentre, Noninterventional Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer.
Colorectal Cancer
SEAMARK – C4221022
Colorectal cancer
The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer.
Prostate Cancer
Prostact-Select
Prostate cancer
Safety, tolerability, biodistribution, dosimetry and efficacy study of 177Lu-DOTA-TLX591-CHO with best standard of care in patients with PSMA expressing metastatic castration-resistant prostate cancer.
Breast Cancer
AUS-PREDICT
Breast cancer
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy.
Prostate Cancer
DASL-HiCaP
Prostate cancer
The purpose of this study is to see if a new drug, darolutamide, combined with the current best treatments, can improve outcomes for people with prostate cancer.
Cancer
DYNAMIC-III
Bowel cancer
The aim of this study is to compare treatment informed by ctDNA results to standard care in patients with stage III colon cancer.
Prostate Cancer
CUPID
Prostate cancer
This study will consist of four groups with the initial three groups undergoing dose escalation and the fourth group will be to confirm the optimal dose and imaging conditions.
Lung Cancer
AdvanTIG – BGB-A317-A1217-302
Non-small cell lung cancer
The purpose of the study is to compare progression-free survival between Arm A and Arm B as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1.
Prostate Cancer
NINJA
Prostate cancer
The NINJA clinical trial aims to compare two emerging schedules of radiotherapy in the treatment of prostate cancer.
Prostate Cancer
ARANOTE
Prostate cancer
This study will assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
Bladder Cancer
Checkmate-078
Bladder cancer
A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC.
Bladder Cancer
BCG + MMC
Bladder cancer
Adding mitomycin C to BCF as adjuvant intravesical therapy for high-risk, non muscle invasive bladder cancer, a randomised phase 3 trial.
Bladder Cancer
KEYPAD
Metastatic kidney cancer
This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).
Cancer
DREAM3R
Mesothelioma
The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.
Skin Cancer
GENTLER
Skin cancer
The purpose of this trial is to see if a reduced radiotherapy can deliver equivalent treatment response to full dose radiotherapy for patients with skin cancer.
Skin Cancer
BFSCT
Skin cancer
This study aims to clinically validate use of the Baker Skin Field Cancerisation Tool (BSFCT) in people attending St Vincent’s Hospital Melbourne dermatology clinic.
Cancer
KEYNOTE-992
Bladder cancer
Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).
CUPisco
Cancer
Phase II targeted therapy or immunotherapy guided by genomic profiling versus platinum based chemotherapy (3C) (after receiving three cycles of platinum based chemotherapy).
Breast Cancer
AVATAR
Breast cancer
Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR).
Breast Cancer
DESTINY-Breast05
Breast cancer
This study will examine the efficacy and safety of trastuzumab deruxtecan compared with trastuzumab emtansine in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.
Skin Cancer
CPOST
Skin cancer
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma.
Prostate Cancer
PRIMORDIUM
Prostate cancer
The hypothesis of study is addition of apalutamide to RT+ LHRHa provides superior efficacy in terms of PSMA-PET metastatic progression-free survival-ppMPFS.
Breast Cancer
CONCERTO
Breast cancer
A comparison of two routinely used skin treatments for women with breast cancer undergoing radiation therapy.
Lung Cancer
B8011011
Carcinoma, non-small-cell lung
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC).
Non-Melanoma Skin Cancer
EVOLVE
Non-melanoma Skin Cancer
Evaluation of Oedema and lymphatic function following volumetric modulated arc therapy for non-melanoma extensive skin field cancerisation of the lower limbs.
Prostate Cancer
Telix ENHANCING
Prostate cancer
The purpose of this study is to determine the effect of androgen deprivation therapy, a treatment commonly prescribed in prostate cancer patients, on the effectiveness of medical imaging techniques.
Cancer
CHALLENGE
Colon cancer
A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High-Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial.
Cancer
ADAPT-MRL
Any cancer
A Long-Term, Prospective and Retrospective, Observational Registry Assessing Technical Data and Clinical Outcomes Following Treatment with MR-Linac.
Lung Cancer
MERMAID-1
Carcinoma, non-small cell lung
The purpose of this study is to assess the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery
Prostate Cancer
PROPELLER
Prostate cancer
The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.
Lung Cancer
MERMAID-2
Carcinoma, non-small cell lung
This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
Prostate Cancer
ENZA-p
Prostate cancer
Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.
Dupuytren's Disease
DEPART
Connective tissue disorders
GenesisCare is recruiting patients with Dupuytren’s Disease for a research study called ‘DEPART’.
NDROR
Skin registry
To collect data to evaluate specified outcomes for patients undergoing radiotherapy for skin cancer and inflammatory skin conditions.
Clinical Trial
EXPERT
Breast cancer
A unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.